Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perfluorocarbons decrease Chlamydophila pneumoniae-mediated inflammatory responses of rat type II pneumocytes in

Heide Wissel1, Wolfram Burkhardt, Jan Rupp

  • 1Clinic for Neonatology, Campus Charité Mitte, D-10098 Berlin, Germany.

Pediatric Research
|July 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Missed opportunities for antibiotic de-escalation among clinically stable adult patients with bloodstream infection: secondary analysis of a prospective, multicenter study.

International journal of antimicrobial agents·2026
Same author

Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.

BMJ open·2026
Same author

Repeated versus selective tactile stimulation for preterm infants at birth: protocol and statistical analysis plan for a stepped-wedge cluster randomised controlled trial (NEU-stim trial).

BMJ open·2026
Same author

Timely, AQL-Driven Clinical Cohort Identification in openEHR Infrastructures.

Studies in health technology and informatics·2026
Same author

Antibiotic pressure does not uncover intra-host heterogeneity of Pseudomonas aeruginosa in patients with chronic lung disease.

BMC microbiology·2026
Same author

Extended Barrier Precautions vs Hand Hygiene Alone and Neonatal Sepsis in Intensive Care Patients: The BALTIC Cluster-Randomized Clinical Trial.

JAMA network open·2026

Perfluorocarbons (PFC) reduce inflammation in lung cells infected with Chlamydophila pneumoniae. PF5080 prevents the release of inflammatory molecules by altering cell membranes, inhibiting bacterial attachment and subsequent immune responses.

Area of Science:

  • Cell Biology
  • Immunology
  • Respiratory Medicine

Background:

  • Chlamydophila pneumoniae infection triggers inflammation in alveolar type II cells via Toll-like receptor 4 (TLR4) activation.
  • This leads to nuclear factor kappaB (NF-kappaB) activation, producing tumor necrosis factor-alpha (TNF-alpha) and macrophage inflammatory protein 2 (MIP-2).
  • Perfluorocarbons (PFCs) show promise in treating bacterial pneumonia by reducing TNF-alpha production.

Purpose of the Study:

  • To investigate if PFCs can prevent C. pneumoniae-induced TNF-alpha and MIP-2 release in isolated alveolar type II cells.
  • To elucidate the underlying molecular pathways involved in PFC-mediated inhibition of inflammation.

Main Methods:

  • Isolated alveolar type II cells were preincubated with PF5080 before C. pneumoniae infection.

Related Experiment Videos

  • Measurements included cytokine (TNF-alpha, MIP-2) secretion, receptor expression (TNF-alpha Receptor 1), and NF-kappaB pathway activation (IkappaBalpha, NF-kappaB p65).
  • Bacterial adherence and internalization were assessed using microscopy.

    • Main Results:

    • PF5080 preincubation significantly reduced C. pneumoniae-induced TNF-alpha and MIP-2 secretion.
    • PF5080 inhibited the increase in TNF-alpha Receptor 1 expression and prevented NF-kappaB activation.
    • PF5080 reduced bacterial adherence to and internalization into alveolar type II cells.

    Conclusions:

    • PF5080 effectively prevents C. pneumoniae-induced inflammatory responses in alveolar type II cells.
    • The mechanism involves preventing NF-kappaB activation and reducing bacterial interaction with the cell.
    • PFCs may exert their beneficial effects by altering the cell membrane, thereby inhibiting the inflammatory cascade.